Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Syro, Luis V., Rotondo, Fabio, Camargo, Mauricio, Ortiz, Leon D., Serna, Carlos A., Kovacs, Kalman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://www.ncbi.nlm.nih.gov/pubmed/29963012
http://dx.doi.org/10.3389/fendo.2018.00318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013558/
https://www.ncbi.nlm.nih.gov/pubmed/29963012
http://dx.doi.org/10.3389/fendo.2018.00318

Ejemplares similares